Literature DB >> 22021924

Unrecognized ingestion of Toxoplasma gondii oocysts leads to congenital toxoplasmosis and causes epidemics in North America.

Kenneth Boyer1, Dolores Hill, Ernest Mui, Kristen Wroblewski, Theodore Karrison, J P Dubey, Mari Sautter, A Gwendolyn Noble, Shawn Withers, Charles Swisher, Peter Heydemann, Tiffany Hosten, Jane Babiarz, Daniel Lee, Paul Meier, Rima McLeod.   

Abstract

BACKGROUND: Congenital toxoplasmosis presents as severe, life-altering disease in North America. If mothers of infants with congenital toxoplasmosis could be identified by risks, it would provide strong support for educating pregnant women about risks, to eliminate this disease. Conversely, if not all risks are identifiable, undetectable risks are suggested. A new test detecting antibodies to sporozoites demonstrated that oocysts were the predominant source of Toxoplasma gondii infection in 4 North American epidemics and in mothers of children in the National Collaborative Chicago-based Congenital Toxoplasmosis Study (NCCCTS). This novel test offered the opportunity to determine whether risk factors or demographic characteristics could identify mothers infected with oocysts.
METHODS: Acutely infected mothers and their congenitally infected infants were evaluated, including in-person interviews concerning risks and evaluation of perinatal maternal serum samples.
RESULTS: Fifty-nine (78%) of 76 mothers of congenitally infected infants in NCCCTS had primary infection with oocysts. Only 49% of these mothers identified significant risk factors for sporozoite acquisition. Socioeconomic status, hometown size, maternal clinical presentations, and ethnicity were not reliable predictors.
CONCLUSIONS: Undetected contamination of food and water by oocysts frequently causes human infections in North America. Risks are often unrecognized by those infected. Demographic characteristics did not identify oocyst infections. Thus, although education programs describing hygienic measures may be beneficial, they will not suffice to prevent the suffering and economic consequences associated with congenital toxoplasmosis. Only a vaccine or implementation of systematic serologic testing of pregnant women and newborns, followed by treatment, will prevent most congenital toxoplasmosis in North America.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22021924      PMCID: PMC3246875          DOI: 10.1093/cid/cir667

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  28 in total

1.  NALP1 influences susceptibility to human congenital toxoplasmosis, proinflammatory cytokine response, and fate of Toxoplasma gondii-infected monocytic cells.

Authors:  William H Witola; Ernest Mui; Aubrey Hargrave; Susan Liu; Magali Hypolite; Alexandre Montpetit; Pierre Cavailles; Cordelia Bisanz; Marie-France Cesbron-Delauw; Gilbert J Fournié; Rima McLeod
Journal:  Infect Immun       Date:  2010-11-22       Impact factor: 3.441

2.  Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis.

Authors:  D V Patel; E M Holfels; N P Vogel; K M Boyer; M B Mets; C N Swisher; N J Roizen; L K Stein; M A Stein; J Hopkins; S E Withers; D G Mack; R A Luciano; P Meier; J S Remington; R L McLeod
Journal:  Radiology       Date:  1996-05       Impact factor: 11.105

3.  Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study.

Authors:  Rima McLeod; Kenneth Boyer; Theodore Karrison; Kristen Kasza; Charles Swisher; Nancy Roizen; Jessica Jalbrzikowski; Jack Remington; Peter Heydemann; A Gwendolyn Noble; Marilyn Mets; Ellen Holfels; Shawn Withers; Paul Latkany; Paul Meier
Journal:  Clin Infect Dis       Date:  2006-04-11       Impact factor: 9.079

4.  Multiple cases of acquired toxoplasmosis retinitis presenting in an outbreak.

Authors:  A J Burnett; S G Shortt; J Isaac-Renton; A King; D Werker; W R Bowie
Journal:  Ophthalmology       Date:  1998-06       Impact factor: 12.079

5.  Human immunome, bioinformatic analyses using HLA supermotifs and the parasite genome, binding assays, studies of human T cell responses, and immunization of HLA-A*1101 transgenic mice including novel adjuvants provide a foundation for HLA-A03 restricted CD8+T cell epitope based, adjuvanted vaccine protective against Toxoplasma gondii.

Authors:  Hua Cong; Ernest J Mui; William H Witola; John Sidney; Jeff Alexander; Alessandro Sette; Ajesh Maewal; Rima McLeod
Journal:  Immunome Res       Date:  2010-12-03

6.  Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy.

Authors:  Joseph D Benevento; Rama D Jager; A Gwendolyn Noble; Paul Latkany; William F Mieler; Mari Sautter; Sanford Meyers; Marilyn Mets; Michael A Grassi; Peter Rabiah; Kenneth Boyer; Charles Swisher; Rima McLeod
Journal:  Arch Ophthalmol       Date:  2008-08

7.  Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group.

Authors:  R McLeod; D Mack; R Foss; K Boyer; S Withers; S Levin; J Hubbell
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

8.  Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial.

Authors:  J McAuley; K M Boyer; D Patel; M Mets; C Swisher; N Roizen; C Wolters; L Stein; M Stein; W Schey
Journal:  Clin Infect Dis       Date:  1994-01       Impact factor: 9.079

Review 9.  Why prevent, diagnose and treat congenital toxoplasmosis?

Authors:  Rima McLeod; Francois Kieffer; Mari Sautter; Tiffany Hosten; Herve Pelloux
Journal:  Mem Inst Oswaldo Cruz       Date:  2009-03       Impact factor: 2.743

10.  Neurologic and developmental outcome in treated congenital toxoplasmosis.

Authors:  N Roizen; C N Swisher; M A Stein; J Hopkins; K M Boyer; E Holfels; M B Mets; L Stein; D Patel; P Meier
Journal:  Pediatrics       Date:  1995-01       Impact factor: 7.124

View more
  51 in total

1.  Oral oocyst-induced mouse model of toxoplasmosis: effect of infection with Toxoplasma gondii strains of different genotypes, dose, and mouse strains (transgenic, out-bred, in-bred) on pathogenesis and mortality.

Authors:  J P Dubey; L R Ferreira; J Martins; Rima McLeod
Journal:  Parasitology       Date:  2011-11-14       Impact factor: 3.234

Review 2.  Long-Term Relationships: the Complicated Interplay between the Host and the Developmental Stages of Toxoplasma gondii during Acute and Chronic Infections.

Authors:  Kelly J Pittman; Laura J Knoll
Journal:  Microbiol Mol Biol Rev       Date:  2015-12       Impact factor: 11.056

3.  Reply to Wallon and Peyron.

Authors:  Rima McLeod; Kelsey M Wheeler; Kenneth Boyer
Journal:  Clin Infect Dis       Date:  2015-12-21       Impact factor: 9.079

Review 4.  Toxoplasma gondii: Biological Parameters of the Connection to Schizophrenia.

Authors:  Jianchun Xiao; Emese Prandovszky; Geetha Kannan; Mikhail V Pletnikov; Faith Dickerson; Emily G Severance; Robert H Yolken
Journal:  Schizophr Bull       Date:  2018-08-20       Impact factor: 9.306

Review 5.  Transmission and epidemiology of zoonotic protozoal diseases of companion animals.

Authors:  Kevin J Esch; Christine A Petersen
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

6.  Novel interpretation of molecular diagnosis of congenital toxoplasmosis according to gestational age at the time of maternal infection.

Authors:  Yvon Sterkers; Francine Pratlong; Sahar Albaba; Julie Loubersac; Marie-Christine Picot; Vanessa Pretet; Eric Issert; Pierre Boulot; Patrick Bastien
Journal:  J Clin Microbiol       Date:  2012-10-03       Impact factor: 5.948

7.  Fetomaternal and Pediatric Toxoplasmosis.

Authors:  Helieh S Oz
Journal:  J Pediatr Infect Dis       Date:  2017-12       Impact factor: 0.293

8.  Design, synthesis, and biological activity of diaryl ether inhibitors of Toxoplasma gondii enoyl reductase.

Authors:  Gang Cheng; Stephen P Muench; Ying Zhou; Gustavo A Afanador; Ernest J Mui; Alina Fomovska; Bo Shiun Lai; Sean T Prigge; Stuart Woods; Craig W Roberts; Mark R Hickman; Patty J Lee; Susan E Leed; Jennifer M Auschwitz; David W Rice; Rima McLeod
Journal:  Bioorg Med Chem Lett       Date:  2013-02-13       Impact factor: 2.823

9.  Discrimination of potent inhibitors of Toxoplasma gondii enoyl-acyl carrier protein reductase by a thermal shift assay.

Authors:  Gustavo A Afanador; Stephen P Muench; Martin McPhillie; Alina Fomovska; Arne Schön; Ying Zhou; Gang Cheng; Jozef Stec; Joel S Freundlich; Hong-Ming Shieh; John W Anderson; David P Jacobus; David A Fidock; Alan P Kozikowski; Colin W Fishwick; David W Rice; Ernesto Freire; Rima McLeod; Sean T Prigge
Journal:  Biochemistry       Date:  2013-12-13       Impact factor: 3.162

Review 10.  Molecules to modeling: Toxoplasma gondii oocysts at the human-animal-environment interface.

Authors:  Elizabeth VanWormer; Heather Fritz; Karen Shapiro; Jonna A K Mazet; Patricia A Conrad
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2012-12-04       Impact factor: 2.268

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.